To compare disease-free survival (DFS), overall survival (s), and toxicity of high-isk primary breast cancer patients with negative axillary lymph nodes or with one to three positive nodes. Conclusion of the study [clinicaltrials_resource:cdbc2dc3aecc685751eca16c4a87e3a9]
High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
To compare disease-free survival (DFS), overall survival (s), and toxicity of high-isk primary breast cancer patients with negative axillary lymph nodes or with one to three positive nodes. Conclusion of the study [clinicaltrials_resource:cdbc2dc3aecc685751eca16c4a87e3a9]
High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
Bio2RDF identifier
cdbc2dc3aecc685751eca16c4a87e3a9
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:cdbc2dc3aecc685751eca16c4a87e3a9
measure [clinicaltrials_vocabulary:measure]
To compare disease-free surviv ...... h one to three positive nodes.
time frame [clinicaltrials_vocabulary:time-frame]
Conclusion of the study
description
High-dose doxorubicin + cyclop ...... xifen 20 mg daily for 5 years.
identifier
clinicaltrials_resource:cdbc2dc3aecc685751eca16c4a87e3a9
title
To compare disease-free surviv ...... nodes. Conclusion of the study
@en
type
label
To compare disease-free surviv ...... c2dc3aecc685751eca16c4a87e3a9]
@en